Royalty Report: Drugs, Kidneys, Disease – Collection: 26257

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 4

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 4

Primary Industries

  • Drugs
  • Kidneys
  • Disease
  • Pharmaceuticals
  • Dialysis
  • Cancer
  • Autoimmune

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 26257

License Grant
With this amendment Licensor now grants a worldwide, exclusive license under jointly held patents to develop, manufacture and commercialize OMONTYS.

The amendment effectuated a transfer of regulatory responsibilities.

License Property
OMONTYS, or peginesatide, injection is for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent designed to stimulate production of red blood cells.

IPSCIO Record ID: 203264

License Grant
Licensor grants to the Japanese Licensee exclusive rights to the Products and certain backup compounds.

Licensor grants an exclusive license under the Licensors Technology to use and import Hematide in the Field in the Licensed Territory, to Develop, use, sell, offer for sale, and import the Bulk API, or Hematide in bulk form, and/or the Product in the Field in the Licensed Territory, and to make and have made the Finished Product anywhere in the world for such Development or sale in the Field in the Licensed Territory.  

Licensor grants to Licensee, during the Term, an exclusive license within the Licensed Territory to use and display the Product Trademarks and Licensors House Marks solely in the Promotional Materials and the Product Labeling in connection with the Commercialization of the Product within the Licensed Territory; provided that such license shall be co-exclusive with Licensor in the U.S. and further that Licensor may use such co-exclusive right solely for the Commercialization of the Product within the U.S. with Licensor.

License Property
“Product” means a pharmaceutical preparation in any formulation that contains Hematide.

“Product Trademark” means the mark “HEMATIDE” and any logos or symbols.

The technology refers to the Peptide, Dipeptide, Hematide, Product or their manufacture or use, or any other invention that is otherwise necessary or useful for the Development, Finished Manufacture or Commercialization of the Product.

Hematide, a synthetic, peptide-based, next-generation erythropoiesis- stimulating agent (ESA), is designed to stimulate the production of red blood cells. It is currently being evaluated in four Phase 2 clinical trials in the United States and Europe to treat anemia in chronic kidney disease (CKD) and cancer patients.

Hematide has a completely novel amino acid sequence that is unrelated to erythropoietin, a hormone that stimulates red blood cell formation, or to any other known naturally-occurring human sequences.

Field of Use
The Field means the prevention, treatment or amelioration of any disease or condition in humans.

IPSCIO Record ID: 263343

License Grant
Through this Amendment, the Parties desire to clarify and further establish their respective rights and obligations under the 2002 Agreement, as well as to license certain additional intellectual property rights to Licensee.

This Amendment is to ratify existing Sub-Licenses and Supply Agreements.

The Parties further agree to complete a subsequent Amendment according to the binding terms and consistent with the Commercialization and Technology License Agreement – IV Triferic (IV License) executed on even date to the extent that it would not conflict with this Amendment.

License Property
The Technology is relating to Triferic® soluble ferric pyrophosphate.

Triferic® is a proprietary iron therapy that replaces iron and maintains hemoglobin in dialysis patients without increasing iron stores.  The Company has developed two presentations of Triferic that are added to the dialysate, or Dialysate Triferic.  Triferic is the first and only FDA-approved iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). It is believed Triferic addresses an important unmet need in the treatment of ongoing iron losses and anemia in ESRD patients. Triferics unique mode-of-action distinguishes it from conventional I.V. iron products because Triferic donates iron to transferrin, immediately, and completely, as soon as it enters the blood. The iron bound to transferrin is transported to the bone marrow to make hemoglobin.  Triferic delivers approximately 5 & 7 mg of iron with every hemodialysis.  Triferic is the first and only FDA-approved iron replacement product indicated for the replacement of iron to maintain hemoglobin in adult patients with hemodialysis-dependent chronic kidney disease (HDD-CKD). We believe Triferic addresses an important unmet need in the treatment of ongoing iron losses and anemia in ESRD patients. Triferic s unique mode-of-action distinguishes it from conventional I.V. iron products because Triferic donates iron to transferrin, immediately, and completely, as soon as it enters the blood. The iron bound to transferrin is transported to the bone marrow to make hemoglobin. Triferic delivers approximately 5 & 7 mg of iron with every hemodialysis.

Field of Use
This agreement pertains to the drug industry relating to iron therapy.

IPSCIO Record ID: 337709

License Grant
The parties agree to commercialize fostamatinib in all potential indications, including chronic ITP and AIHA, in Canada and Israel.
License Property
Fostamatinib has the brand name of Tavlesse (Tavalisse). It is a tablet, the only oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic ITP who have had an insufficient response to a previous treatment.

ITP means immune thrombocytopenia where the immune system attacks and destroys the body’s own blood platelets, which play an active role in blood clotting and healing. ITP patients can suffer extraordinary bruising, bleeding and fatigue as a result of low platelet counts.

Field of Use
Field of use is for the treatment of thrombocytopenia in adult patients with chronic ITP who have had an insufficient response to other treatments and to reduce the destruction of red blood cells in the AIHA disease.

AIHA means autoimmune hemolytic anemia.  It is is a rare, serious blood disorder where the immune system produces antibodies that result in the destruction of the bodys own red blood cells. Symptoms can include fatigue, shortness of breath, rapid heartbeat, jaundice or enlarged spleen.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.